Cisplatin & Pemetrexed
Phase 3Small molecule
AstraZenecaCisplatin & Pemetrexed is one of 134 small molecule programs targeting Intrahepatic Cholangiocarcinoma. It is currently in Phase 3.
4
Indications
9
Total Trials
2
Active Trials
133
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1639 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Cisplatin & Pemetrexed
AstraZenecaPhase 3
Yervoy
Bristol-Myers SquibbPreclinical
PORTRAZZA
Eli LillyPreclinical
Vizimpro
PfizerPreclinical
Immunotherapy
Bristol-Myers SquibbPreclinical
Tyrosine Kinase Inhibitor
PfizerPreclinical
PD-1 Inhibitor
Johnson & JohnsonPreclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Treatment
GSKPreclinical
Immune Checkpoint Inhibitor
IImmuneSensor Therapeutics Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer2 trials
Small Cell Lung Cancer2 trials
Intrahepatic Cholangiocarcinoma1 trial
Urothelial Cancer1 trial
Randomized1 trial
A Randomized Phase II Study of SUBATM-itraconazole in Patients With Untreated Squamous NSCLC.
Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT01752023·3 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Cisplatin & Pemetrexed. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company